Literature DB >> 32209383

Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries.

Kin On Kwok1, Florence Lai2, Wan In Wei3, Samuel Yeung Shan Wong3, Julian W T Tang4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32209383      PMCID: PMC7151357          DOI: 10.1016/j.jinf.2020.03.027

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.
Dear Editor, Previous workers have attempted to predict the cumulative number of cases of Coronavirus Disease 2019 (COVID-19) in China. However, since then, the epidemic has rapidly evolved into a pandemic affecting multiple countries worlwide. There have been serious debates about how to react to the spread of this disease, particularly by European countries, such as Italy, Spain, Germany, France and the UK, e.g. from closing schools and universities to locking down entire cities and countries. An alternative strategy would be to allow the causal virus (SARS-CoV-2) to spread to increase the population herd immunity, but at the same time protecting the elderly and those with multiple comorbidities, who are the most vulnerable to this virus. Before initiating either of these strategies, we need to estimate the basic reproductive number (R0), or the more ‘real-life’ effective reproductive number (Rt) for a given population. R0 is the number of secondary cases generated by the presence of one infected individual in an otherwise fully susceptible, well-mixed population. Rt is a more practical real-life version of this, which uses real-life data (from diagnostic testing and/or clinical surveillance) to estimate the reproductive number for an ongoing epidemic. For this anaylsis, we will estimate Rt, and we can do this by applying the exponential growth method, using data on the daily number of new COVID-19 cases, together with a recent estimate of the serial interval (mean = 4.7 days, standard deviation = 2.9 days), at a 0.05 significance level, with the mathematical software R (v3.6.1.). Using these values of Rt, we can then calculate the minimum (‘critical’) level of population immunity, Pcrit, acquired via vaccination or naturally-induced (i.e. after recovery from COVID-19), to halt the spread of infection in that population, using the formula: Pcrit= 1-(1/Rt). So, for example, if the value of Rt = 3 then Pcrit= 0.67, i.e. at least two-thirds of the population need to be immune. As of 13 March 2020, there were 32 countries outside China with over 100 COVID-19 cases. The seven countries with the highest number of infections were: the United States (n = 2294), France (n = 3671), Germany (n = 3675), Spain (n = 5232), Korea (n = 8086), Iran (n = 11,364) and Italy (n = 17,660). The number of confirmed cases in the other 25 countries were less than 1200 (Table 1 ).
Table 1

Estimates of SARS-CoV-2 effective reproduction number (Rt) of 32 study countries (as of 13 March 2020,), and the minimum proportion (Pcrit, as% of population) needed to have recovered from COVID-19 with subsequent immunity, to halt the epidemic in that population.

Study countriesPopulation infected by COVID-19Estimates of effective reproduction number (Rt) (95% CI), (n = 32)Minimum proportion (%) of total population required to recover from COVID-19 to confer immunity (Pcrit)
Rt >4
Bahrain2106.64 (5.20, 8.61)85.0
Slovenia1416.38 (4.91, 8.38)84.3
Qatar3205.38 (4.59, 6.34)81.4
Spain52325.17 (4.98, 5.37)80.7
Denmark8045.08 (4.60, 5.62)80.3
Finland1554.52 (3.72, 5.56)77.9
Rt (2–4)
Austria5043.97 (3.56, 4.42)74.8
Norway9963.74 (3.47, 4.04)73.3
Portugal1123.68 (2.86, 4.75)72.8
Czech Republic1413.57 (2.88, 4.45)72.0
Sweden8143.44 (3.20, 3.71)70.9
The United States22943.29 (3.15, 3.43)69.6
Germany36753.29 (3.18, 3.40)69.6
Switzerland11393.26 (3.05, 4.78)69.3
Brazil1513.26 (2.99, 3.55)69.3
Netherlands8043.25 (3.02, 3.51)69.2
Greece1903.12 (2.67, 3.67)67.9
France36613.09 (2.99, 3.19)67.6
Israel1433.02 (2.56, 3.59)66.9
The United Kingdom7982.90 (2.72, 3.10)65.5
Italy17,6602.44 (2.41, 2.47)59.0
Canada1982.30 (2.07, 2.57)56.5
Iceland1342.28 (1.90, 2.75)56.1
Rt (1–2)
Iran11,3642.00 (1.96, 2.03)50.0
Australia1991.86 (1.71, 2.03)46.2
Belgium5591.75 (1.55, 1.97)42.9
Malaysia1971.74 (1.61, 1.88)42.5
Iraq1011.67 (1.41,1.97)40.1
Japan7341.49 (1.44, 1.54)32.9
Korea80861.43 (1.42, 1.45)30.1
Singapore2001.13 (1.06, 1.19)11.5
Kuwait1001.06 (0.89, 1.26)5.66
Estimates of SARS-CoV-2 effective reproduction number (Rt) of 32 study countries (as of 13 March 2020,), and the minimum proportion (Pcrit, as% of population) needed to have recovered from COVID-19 with subsequent immunity, to halt the epidemic in that population. Exploring these parameters and their implications further, the difference between R0 and Rt is related to the proportion of individuals that are already immune (either by vaccination or natural infection) to that pathogen in that population. So another way of calculating Rt for a pathogen in a given population is by multiplying R0 by the proportion of that population that is non-immune (i.e. susceptible) to that pathogen. Hence, R0 will only equal Rt when there are no immune individuals in the population (i.e. when all are susceptible). This means that any partial, pre-existing immunity to the infecting agent can reduce the number of expected secondary cases arising. Although SARS-CoV-2 is a new coronavirus, one source of possible partial immunity to is some possible antibody cross-reactivity and partial immunity from previous infections with the common seasonal coronaviruses (OC43, 229E, NL63, HKU1) that have been circulating in human populations for decades, as was noted for SARS-CoV. This could also be the case for SARS-CoV-2 and might explain why some individuals (perhaps those who have recently recovered from a seasonal coronavirus infection) have milder or asymptomatic infections. Finally, returning to the concept of enhancing herd immunity to control the COVID-19 epidemic, given that the case fatality rate (CFR) of COVID-19 can be anything between 0.25–3.0% of a country's population, the estimated number of people who could potentially die from COVID-19, whilst the population reaches the Pcrit herd immunity level, may be difficult to accept.
  6 in total

1.  How generation intervals shape the relationship between growth rates and reproductive numbers.

Authors:  J Wallinga; M Lipsitch
Journal:  Proc Biol Sci       Date:  2007-02-22       Impact factor: 5.349

Review 2.  Serological assays for emerging coronaviruses: challenges and pitfalls.

Authors:  Benjamin Meyer; Christian Drosten; Marcel A Müller
Journal:  Virus Res       Date:  2014-03-23       Impact factor: 3.303

3.  Case-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality.

Authors:  Nick Wilson; Amanda Kvalsvig; Lucy Telfar Barnard; Michael G Baker
Journal:  Emerg Infect Dis       Date:  2020-06-17       Impact factor: 6.883

4.  Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China.

Authors:  Zhiliang Hu; Ci Song; Chuanjun Xu; Guangfu Jin; Yaling Chen; Xin Xu; Hongxia Ma; Wei Chen; Yuan Lin; Yishan Zheng; Jianming Wang; Zhibin Hu; Yongxiang Yi; Hongbing Shen
Journal:  Sci China Life Sci       Date:  2020-03-04       Impact factor: 10.372

5.  Simulating and forecasting the cumulative confirmed cases of SARS-CoV-2 in China by Boltzmann function-based regression analyses.

Authors:  Xinmiao Fu; Qi Ying; Tieyong Zeng; Tao Long; Yan Wang
Journal:  J Infect       Date:  2020-02-26       Impact factor: 6.072

6.  Serial interval of novel coronavirus (COVID-19) infections.

Authors:  Hiroshi Nishiura; Natalie M Linton; Andrei R Akhmetzhanov
Journal:  Int J Infect Dis       Date:  2020-03-04       Impact factor: 3.623

  6 in total
  123 in total

1.  The false promise of herd immunity for COVID-19.

Authors:  Christie Aschwanden
Journal:  Nature       Date:  2020-11       Impact factor: 49.962

2.  How the pandemic might play out in 2021 and beyond.

Authors:  Megan Scudellari
Journal:  Nature       Date:  2020-08       Impact factor: 49.962

3.  Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China.

Authors:  Hengcong Liu; Juanjuan Zhang; Wenhong Zhang; Marco Ajelli; Hongjie Yu; Jun Cai; Xiaowei Deng; Cheng Peng; Xinghui Chen; Juan Yang; Qianhui Wu; Xinhua Chen; Zhiyuan Chen; Wen Zheng; Cécile Viboud
Journal:  BMC Med       Date:  2022-01-31       Impact factor: 8.775

4.  Factors associated with COVID-19 vaccination acceptance among industrial workers in the post-vaccination era: a large-scale cross-sectional survey in China.

Authors:  Di Yin; Hongbiao Chen; Zhaomin Deng; Yue Yuan; Musha Chen; He Cao; Xiaofeng Zhou; Jingwei Luo; Wei Zhang; Zihao Gu; Ziyu Wen; Caijun Sun
Journal:  Hum Vaccin Immunother       Date:  2021-10-29       Impact factor: 3.452

5.  Factors associated with decision making on COVID-19 vaccine acceptance among college students in South Carolina.

Authors:  Cheuk Chi Tam; Shan Qiao; Xiaoming Li
Journal:  Psychol Health Med       Date:  2021-09-23       Impact factor: 2.423

6.  Projected effects of nonpharmaceutical public health interventions to prevent resurgence of SARS-CoV-2 transmission in Canada.

Authors:  Victoria Ng; Aamir Fazil; Lisa A Waddell; Christina Bancej; Patricia Turgeon; Ainsley Otten; Nicole Atchessi; Nicholas H Ogden
Journal:  CMAJ       Date:  2020-08-09       Impact factor: 8.262

7. 

Authors:  Victoria Ng; Aamir Fazil; Lisa A Waddell; Christina Bancej; Patricia Turgeon; Ainsley Otten; Nicole Atchessi; Nicholas H Ogden
Journal:  CMAJ       Date:  2020-11-30       Impact factor: 8.262

8.  An examination of school reopening strategies during the SARS-CoV-2 pandemic.

Authors:  Alfonso Landeros; Xiang Ji; Kenneth Lange; Timothy C Stutz; Jason Xu; Mary E Sehl; Janet S Sinsheimer
Journal:  PLoS One       Date:  2021-05-20       Impact factor: 3.240

9.  Will achieving herd immunity be a road to success to end the COVID-19 pandemic?

Authors:  Kin On Kwok; Edward B McNeil; Margaret Ting Fong Tsoi; Vivian Wan In Wei; Samuel Yeung Shan Wong; Julian Wei Tze Tang
Journal:  J Infect       Date:  2021-06-10       Impact factor: 38.637

10.  On the management of COVID-19 pandemic in Italy.

Authors:  Fabio Gaetano Santeramo; Marco Tappi; Emilia Lamonaca
Journal:  Health Policy       Date:  2021-05-31       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.